LGDN Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Ligand Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 164 EUR

Market Cap: €2.9B

L	Ligand Pharmaceuticals Inc XBER:LGDN	US
C	China Merchants Port Holdings Co Ltd SWB:CPM	HK
	HIAG Immobilien Holding AG F:0HG	CH
C	Chevron Corp XHAM:CHV	US
	LSI Industries Inc NASDAQ:LYTS	US
H	Haypp Group AB (publ) STO:HAYPP	SE
	Amadeus IT Group SA F:AI3A	ES
	Kulicke and Soffa Industries Inc NASDAQ:KLIC	SG
P	Patterson-UTI Energy Inc XMUN:PE1	US
O	ON Semiconductor Corp XMUN:XS4	US
J	J M Smucker Co XBER:JM2	US
	Wynn Resorts Ltd F:WYR	US
T	Tubacex SA SWB:TCX	ES
	Darling Ingredients Inc NYSE:DAR	US
J	JPMorgan Chase & Co XHAM:CMC	US

Profitability Summary

Ligand Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

95%

Strong 3Y Average Gross Margin

90%

Gross Margin is Increasing

74% > 95%

Healthy Operating Margin

18%

Low 3Y Average Operating Margin

Declining Operating Margin

23% > 18%

Exceptional Net Margin

46%

Sustainable 3Y Average Net Margin

15%

Net Margin is Increasing

17% > 46%

Exceptional Free Cash Flow Margin

18%

Strong 3Y Average Free Cash Flow Margin

22%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.